Literature DB >> 31144772

Cancer drugs approved for use in children: Impact of legislative initiatives and future opportunities.

Amy Barone1, Denise Casey1, Amy E McKee2, Gregory Reaman2.   

Abstract

It is well appreciated that the number of anticancer drugs approved for use in children is a fraction of the number approved for use in cancers that occur in adults. We address this fact by summarizing the relevant U.S. legislation that provides the framework for the evaluation and approval of drugs used to treat children with cancer. In total, the Food and Drug Administration (FDA) has approved 38 new drug applications for pediatric oncology indications, 12 of which were new molecular entities. FDA continues to collaborate with multistakeholders regarding the development of products intended for pediatric cancer and encourages the submission of marketing applications. Published 2019. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  FDA; cancer; children; drug approval

Year:  2019        PMID: 31144772     DOI: 10.1002/pbc.27809

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  6 in total

1.  Landscape of phase 1 clinical trials for minors with cancer in the United States.

Authors:  Jaclynne H Nader; Dylan V Neel; David S Shulman; Clement Ma; Florence Bourgeois; Steven G DuBois
Journal:  Pediatr Blood Cancer       Date:  2020-09-04       Impact factor: 3.167

2.  Winning the RACE: Expanding pediatric cancer drug approvals.

Authors:  David S Shulman; Steven G DuBois
Journal:  Pediatr Blood Cancer       Date:  2019-03-11       Impact factor: 3.167

3.  Pediatric Trials for Cancer Therapies With Targets Potentially Relevant to Pediatric Cancers.

Authors:  Thomas J Hwang; Liat Orenstein; Steven G DuBois; Katherine A Janeway; Florence T Bourgeois
Journal:  J Natl Cancer Inst       Date:  2020-03-01       Impact factor: 13.506

Review 4.  The emerging role of pyroptosis in pediatric cancers: from mechanism to therapy.

Authors:  Hua Wang; Xiaowen Zhou; Chenbei Li; Shuxiang Yan; Chengyao Feng; Jieyu He; Zhihong Li; Chao Tu
Journal:  J Hematol Oncol       Date:  2022-10-08       Impact factor: 23.168

5.  Multicenter study of risk factors of unplanned 30-day readmissions in pediatric oncology.

Authors:  Kamila Hoenk; Lilibeth Torno; William Feaster; Sharief Taraman; Anthony Chang; Michael Weiss; Karen Pugh; Brittney Anderson; Louis Ehwerhemuepha
Journal:  Cancer Rep (Hoboken)       Date:  2021-02-02

6.  Off-label prescribing of targeted anticancer therapy at a large pediatric cancer center.

Authors:  Mir Lim; David S Shulman; Holly Roberts; Anran Li; Jessica Clymer; Kira Bona; Hasan Al-Sayegh; Clement Ma; Steven G DuBois
Journal:  Cancer Med       Date:  2020-08-04       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.